Over the past few days, the news from GoodRx Holdings (NASDAQ: GDRX) hasn't been all that good. On Thursday the online ...

GoodRx has been hit with a series of antitrust class actions in California and Rhode Island federal courts challenging the ...

Three independent pharmacies have filed lawsuits accusing GoodRx, which markets a prescription drug discount card, of ...

On Monday, Goodrx Holdings Inc (GDRX) stock saw a modest uptick, ending the day at $4.89 which represents no change from the prior close of of $4.89. The stock opened at $4.98 and touched a low of $4.

Barclays lowered the firm’s price target on GoodRx (GDRX) to $6 from $10 and keeps an Overweight rating on the shares post the Q3 report.

Welcome to the GoodRx third-quarter 2024 earnings call. As a reminder, today's conference call is being recorded. I would now ...

In a report released today, Jailendra Singh from Truist Financial maintained a Hold rating on GoodRx Holdings (GDRX – Research Report), ...

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 59%. Looking ahead, revenue ...

Novo Nordisk disclosed it knows of 10 deaths and 100 hospitalizations from people taking compounded copies of its weight loss ...

Drug coupon aggregator GoodRx and pharmacy benefit managers including CVS Caremark and Express Scripts have been hit with at least three class action lawsuits accusing them of working together to ...

Independent pharmacies have filed 3 class action lawsuits against GoodRx Holdings and major pharmacy benefit managers (PBMs).

GoodRx Holdings Inc (GDRX) reports robust growth in adjusted EBITDA and Pharma Manufacturer Solutions revenue, despite facing ...